Wednesday, December 8, 2021
8:15–10:15 PM AT | 7:15–9:15 PM ET | 6:15–8:15 PM CT | 5:15–7:15 PM MT | 4:15–6:15 PM PT
Free for CSEM members; $60 for non-members

Moderated by Dr. Hertzel Gerstein, this two-hour, accredited online symposium features a review of the key scientific developments in endocrinology and diabetes over the past year. Dr. Amel Arnaout and Dr. Jeremy Gilbert will synthesize and discuss within the Canadian context research from major conferences such as ENDO Society, EASD and ADA.

At the end of this symposium, participants will be able to:

• synthesize key scientific developments in diabetes and endocrinology over the past year
• evaluate the relevance and implications for diabetes management within a Canadian context
• identify important elements of emerging research that can be applied to clinical practice

For more information on this event, click here.

To register for the CSEM Diabetes & Endocrinology Research Year-in-Review, click here.

This learning activity was planned independently by CSEM to achieve scientific integrity, objectivity, and balance. CSEM received educational grants from: Lilly, Novo Nordisk and Sanofi.

CSEM congratulates past-president Dr. André Lacroix on his International Society of Endocrinology (ISE) volunteer work. As his term as immediate past-Chairperson has come to an end, Dr. Lacroix was recognized with a short video at the ISE Annual General Meeting this October for his many accomplishments on the ISE executive. Dr. Lacroix served as President of ISE from 2016–2020 promoting international collaboration within the global endocrine community. Dr. Lacroix was President of CSEM from 2005–2007 and most recently chaired CSEM’s Cushing’s Disease symposium: Choices, Challenges and Complications (available for members here).

With the continued uncertainty related to the COVID-19 pandemic, Diabetes Canada, CSEM, and the National Planning Committee have collectively decided to offer the 2021 Professional Conference as a virtual experience from November 23–26, 2021.

Registration is now open, click here!

Abstract submission is now open!

• Abstracts for the CSEM general endocrinology and metabolism program are now being accepted for the 2021 Diabetes Canada/CSEM Professional Conference. Submissions are accepted from researchers, endocrinologists and trainees. Submit within the next week to take advantage of the early bird rate for $25.00 per abstract until Wednesday, May 19, 2021, 5:00 PM EDT. After May 19, the regular fee will be $45.00. Abstract submission closes on Wednesday, June 2, 2021, 11:59 PM EDT. Click here to submit a general abstract.
• CSEM is now accepting abstracts for resident clinical vignettes or proposed/in-progress basic science or translational research projects. Oral presentations and e-posters will be pre-recorded and presented virtually during the 2021 Diabetes Canada/CSEM Professional Conference. Submission deadline: Monday, September 6, 2021 at 11:59 PM EDT. Click here to submit a resident clinical vignette or proposed research project abstract.

The conference website will be updated as more information becomes available.

CSEM has received questions from its members regarding the eligibility and safety of the COVID-19 vaccines and patients with endocrine conditions. Health Canada recommendations are changing rapidly. Recognizing there is little data to address groups excluded in the vaccine trials, a risk benefit assessment will need to be case-by-case and in consideration of national, provincial and local regulations.

CSEM supports equitable access to COVID-19 vaccines for individuals with endocrine conditions. Patients with type 1 diabetes, other autoimmune conditions, and immunocompromised health should have a risk/benefit discussion with their health care provider to make an informed decision. Some patients have multiple comorbidities that affect their vaccine status and patients may need to discuss with the relevant specialist(s).

Please see our statement for resources and references, including Diabetes Canada's statement.

View the CSEM 2020 Annual Report here.